Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3).
暂无分享,去创建一个
H. Katayama | H. Watari | N. Sakuragi | K. Ushijima | T. Onda | N. Yaegashi | D. Aoki | T. Shibata | T. Satoh | H. Fukuda
[1] H. Yoshikawa,et al. Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms , 2016, International Journal of Clinical Oncology.
[2] P. Dong,et al. Distribution of Lymph Node Metastasis Sites in Endometrial Cancer Undergoing Systematic Pelvic and Para-Aortic Lymphadenectomy: A Proposal of Optimal Lymphadenectomy for Future Clinical Trials , 2014, Annals of Surgical Oncology.
[3] M. Kaneuchi,et al. A Retrospective Analysis of Postoperative Complications With or Without Para-aortic Lymphadenectomy in Endometrial Cancer , 2011, International Journal of Gynecologic Cancer.
[4] M. Kaneuchi,et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis , 2010, The Lancet.
[5] N. Sakuragi,et al. Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group. , 2009, Gynecologic oncology.
[6] V. Torri,et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.
[7] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .
[8] M. Parmar,et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.
[9] N. Hacker,et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. , 2005, Journal of the National Cancer Institute.
[10] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[11] D. Schoenfeld,et al. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.
[12] Nobuyuki Susumu,et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.
[13] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.